{
    "nctId": "NCT00569283",
    "briefTitle": "Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant",
    "officialTitle": "Donor Natural Killer Cell Infusion for the Prevention of Relapse or Graft Failure After HLA-Haploidentical Familial Donor Bone Marrow Transplantation-A Phase I Study",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "Maximum tolerated dose of donor natural killer (NK) cells",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Has undergone HLA-haploidentical familial donor bone marrow transplantation within the past 4-6 weeks\n* No manifestations of acute graft-vs-host disease at the time of planned donor natural killer cell infusion\n\nPATIENT CHARACTERISTICS:\n\n* Karnofsky performance status 70-100%\n* Bilirubin \\< 2.0 mg/dL\n* AST \\< 3 times upper limit of normal\n* Creatinine \\< 2.0 mg/dL\n* Ejection fraction \\> 40% on MUGA scan\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}